Mary McCormack

Universitat Jaume I — Spain

Medicine · Health Sciences

27h-index4.0kcitations129works8.12yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Endometrial and Cervical Cancer Treatments(78), Ovarian cancer diagnosis and treatment(38), Cervical Cancer and HPV Research(18), Endometriosis Research and Treatment(13), Colorectal and Anal Carcinomas(12)

Publications129 total

Adjuvant Chemoradiotherapy Versus Radiotherapy Alone in Women With High-Risk Endometrial Cancer (PORTEC-3): 10-Year Clinical Outcomes and Post Hoc Analysis by Molecular Classification From a Randomized Phase 3 Trial
Obstetrical & Gynecological Survey·2025
Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): 10-year clinical outcomes and post-hoc analysis by molecular classification from a randomised phase 3 trial
The Lancet Oncology·2025· 12 citedOpen Access
INTERLACE: not a new standard for cervical cancer chemoradiation – Authors' reply
The Lancet·2025Open Access
Response to letter Re: Induction chemotherapy followed by chemoradiation in locally advanced cervical cancer: Quality of life outcomes of the GCIG INTERLACE trial
European Journal of Cancer·2025
Induction chemotherapy followed by chemoradiation in locally advanced cervical cancer: Quality of life outcomes of the GCIG INTERLACE trial
European Journal of Cancer·2025· 4 citedOpen Access
Induction Chemotherapy Followed by Standard Chemoradiotherapy Versus Standard Chemoradiotherapy Alone in Patients With Locally Advanced Cervical Cancer (GCIG INTERLACE): An International, Multicentre, Randomised Phase 3 Trial
Obstetrical & Gynecological Survey·2025
INTERLACE in practice
International Journal of Gynecological Cancer·2024· 1 cited
Ethnicity and Socioeconomic Disparities in Clinical Trial Participation for Ovarian Cancer: A Retrospective Observational Study in London
Cancers·2024· 1 citedOpen Access
A randomized, phase III trial of induction chemotherapy followed by chemoradiation compared with chemoradiation alone in locally advanced cervical cancer: The GCIG INTERLACE Trial
Gynecologic Oncology·2024
Induction chemotherapy followed by standard chemoradiotherapy versus standard chemoradiotherapy alone in patients with locally advanced cervical cancer (GCIG INTERLACE): an international, multicentre, randomised phase 3 trial
The Lancet·2024· 111 citedOpen Access
A multicenter retrospective study to assess feasibility, safety and efficacy of first-line carboplatin-paclitaxel versus carboplatin monotherapy in a frail, elderly epithelial ovarian cancer population☆
International Journal of Gynecological Cancer·2024· 1 cited
710MO Induction chemotherapy followed by chemoradiation in locally advanced cervical cancer: Quality of life outcomes of the GCIG INTERLACE trial
Annals of Oncology·2024· 1 cited
Highlights from the 25th European Congress on Gynaecological Oncology in Barcelona: the ENYGO-IJGC Fellow Interviews
International Journal of Gynecological Cancer·2024
A non-comparative, randomized, phase II trial of atezolizumab or atezolizumab plus tiragolumab for programmed death-ligand 1-positive recurrent cervical cancer (SKYSCRAPER-04)
International Journal of Gynecological Cancer·2024· 22 cited
Current Management Practices for Endometrial Cancer (EC) in the UK: A National Healthcare Professional Survey (KNOW-EC)
Clinical Oncology·2024Open Access
Outcomes of minimal access retroperitoneal para-aortic lymphadenectomy in patients with locally advanced cervical cancer
Journal of Obstetrics and Gynaecology·2024· 1 citedOpen Access
3408: Ten-year results of the PORTEC-3 trial: adjuvant therapy for women with high-risk endometrial cancer
Radiotherapy and Oncology·2024
Abstract 5179: Tumor microenvironment (TME) biomarkers of TIGIT and PD-L1 immune checkpoint blockade in cervical cancer: An exploratory biomarker analysis from SKYSCRAPER-04 (SKY04) study
Cancer Research·2024
842 Outcomes in mucinous ovarian/fallopian tube cancer (MOC); real world outcomes from two tertiary London centres
2024
PO002/#156  Efficacy and safety results from skyscraper-04: an open-label randomized phase 2 trial of tiragolumab plus atezolizumab for PD-L1-positive recurrent cervical cancer
2023· 1 citedOpen Access
page 1 of 7Next →

Frequent Co-authors

Jonathan A. Ledermann(11), Gemma Eminowicz(8), Linda Mileshkin(7), Remi A. Nout(7), Sandro Pignata(7), Melanie Powell(6), Henry C Kitchener(6), Carien L. Creutzberg(6), Stephanie M. de Boer(5), Dionyssios Katsaros(5), Christine Haie-Méder(5), Pearly Khaw(5), Anthony Fyles(5), Ina M. Jürgenliemk‐Schulz(5), Hans W. Nijman(5), Viet Do(5), Romerai D’Amico(5), Amanda Feeney(5), Hein Putter(5), Karen Whitmarsh(5)